Table 2 Characteristics of study patients.
Characteristics | Intervention group (n = 1256) | Control group (n = 1131) | All patients (n = 2387) | Statistical testing |
|---|---|---|---|---|
Gender, female, n (%) | 683 (54.4%) | 615 (54.4%) | 1298 (54.4%) | Chi-Square p = 0.99 |
Age, years (means, SE) | 64.71 (± 12.71) | 64.19 (± 13.19) | 64.46 (± 12.94) | p = 0.373* |
PPI agent, n (%) | ||||
Pantoprazol | 751 (66.2%) | 646 (62.5%) | 1397 (64.4%) | Fisher’s Exact Test, p = 0.18 |
Omeprazol | 328 (28.7%) | 316 (30.8%) | 644 (29.7%) | |
Esomeprazol | 52 (4.6%) | 66 (6.4%) | 118 (5.4%) | |
Lansoprazol | 5 (0.4%) | 4 (0.4%) | 9 (0.4%) | |
Dexlansoprazol | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Rabeprazol | 1 (0.1%) | 0 (0.0%) | 1 (0.05%) | |
PPI DDD (means, SE) | 256 (± 7.9) | 244 (± 8.1) | 250 (± 8.0) | p = 0.292* |
Intake duration, years (means, SE) | 5.46 (± 4.40) | 5.14 (± 4.37) | 5.30 (± 4.39) | p = 0.002, Cohen’s d = 0.19 |
Indication, n (%) | ||||
Peptic ulcer | 72 (7.0%) | 78 (7.8%) | 150 (7.4%) | Chi-square p = 0.48 |
Gastroesophageal reflux | 508 (40.1%) | 481 (42.5%) | 989 (41.4) | Chi-square p = 0.66 |
Barrett's esophagus | 97 (7.7%) | 73 (6.5%) | 170 (7.1%) | Chi-square p = 0.09 |
Chronic gastritis | 168 (13.4%) | 214 (18.9%) | 382 (16.0%) | Chi-square p = 0.003, Cramér-V = 0.066 |
Gastroprotection | 368 (29.3%) | 289 (25.6%) | 657 (27.5%) | Chi-square p = 0.001, Cramér-V = 0.072 |
Post hospital stay | 64 (5.1%) | 87 (7.7%) | 151 (6.3%) | Chi-square p = 0.03, Cramér-V = 0.048 |
Unclear | 25 (2.0%) | 57 (5.0%) | 82 (3.4%) | Chi-square p < 0.001, Cramér-V = 0.084 |
